Hypoxia enhances the protective effects of placenta-derived mesenchymal stem cells against scar formation through hypoxia-inducible factor-1α

Du, Lili; Lv, Runxiao; Yang, Xiaoyi; Cheng, Shaohang; Xu, Jing; Ma, Tiantian

doi:10.1007/s10529-016-2067-6

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well established that P-MSCs secreted a number of proangiogenic factors such as vascular endothelial growth factor (VEGF) in vitro, and those were largely increased in hypoxia condition [8,[18][19][20], which seems to be consistent with the ischemic situation for diabetic patients. Another study confirmed the angiogenic paracrine activity of P-MSCs through expressing high levels of hepatocyte growth factor (HGF) [21].…”

Section: Discussionmentioning

confidence: 72%

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Wang

Zeng

Cai

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Aim Diabetic foot has become the main cause of non-traumatic amputation. Stem cell therapy, especially mesenchymal stem cells (MSCs), holds a great promise as a therapy for diabetic foot with ischemia limb arterial disease. The aim of this pilot study is to evaluate the safety and efficacy of placenta-derived MSCs (P-MSCs) treatment for diabetic patients with critical limb ischemia (CLI). Methods Four eligible diabetic patients with CLI were consecutively enrolled in this pilot study. On the base of the standard-of-care treatment, these patients accepted P-MSCs treatment by intramuscular injection for successive 3 times at an interval of 4 weeks, and the safety and efficacy of placenta-derived MSCs (P-MSCs) treatment were evaluated. Results There were no serious adverse events during the period of P-MSCs injection and the 24-weeks follow-up period. The clinical ischemic features of patients were improved 24 weeks after P-MSCs treatment. The scores of resting pain and limb coldness significantly decreased, and pain-free walking distance significantly increased from baseline to 24 weeks after P-MSCs therapy. The resting ankle brachial index increased, but no statistically significant difference was found. The findings of magnetic resonance angiography showed the increase of collateral vessel formation in one patient, but there were no significant changes observed in the other patients. Conclusions The data in this pilot study indicated that multiple intramuscular P-MSCs injections may be a safe and effective alternative therapy for diabetic patients with CLI, and larger, placebo-controlled, perspective studies are needed to prove these results.

show abstract

Section: Discussionmentioning

confidence: 72%

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Wang

Zeng

Cai

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…To obtain CM, MSCs were mainly isolated from human tissues: adipose tissue (Li et al, 2016;Choi et al, 2017;Liu et al, 2018) (33.33%, 3/9), umbilical cord blood (Arjunan et al, 2020), placenta (Du et al, 2016a), and bone marrow (Wu et al, 2015). Murine bone marrow (Hu et al, 2020), murine placenta (Du et al, 2016b), and rabbit adipose tissue (Zhang et al, 2015) were also used. CM was collected from MSCs between passages 3 and 13 at 70-90% confluence.…”

Section: Preclinical Studiesmentioning

confidence: 99%

Mesenchymal Stromal Cell-Conditioned Medium for Skin Diseases: A Systematic Review

Montero‐Vílchez

Sierra-Sánchez

Sánchez‐Díaz

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The skin is the largest organ of the human body, and its dysfunction is related to many diseases. There is a need to find new potential effective therapies for some skin conditions such as inflammatory diseases, wound healing, or hair restoration. Mesenchymal stromal cell (MSC)-conditioned medium (CM) provides a potential opportunity in the treatment of skin disease. Thus, the objective of this review is to evaluate the uses of MSC-CM for treating skin diseases in both animal and human models. A systematic review was conducted regarding the use of MSC-CM for treating skin conditions. One hundred one studies were analyzed. MSC-CM was evaluated in wound healing (55), hypertrophic scars (9), flap reperfusion (4), hair restoration (15), skin rejuvenation (15), and inflammatory skin diseases (3). MSC-CM was obtained from different MSC sources, mainly adipose tissue, bone marrow, and umbilical cord blood. MSC-CM was tested intravenously, intraperitoneally, subcutaneously, intradermally or intralesionally injected or topically applied. MSC-CM was used in both animals and humans. MSC-CM improved wound healing, hair restoration, skin rejuvenation, atopic dermatitis, and psoriasis in both animals and humans. MSC-CM also decreased hypertrophic scars and flap ischemia in animal models. In conclusion, MSC-CM is a promising therapy for skin conditions. Further studies are needed to corroborate safety and effectiveness and to standardize CM manufacturing.

show abstract

“…One master regulator of angiogenesis, a critical process in wound healing, is hypoxia-inducible factor-1α (HIF-1α). HIF-1α has been shown to be a significant component for appropriate wound healing in a number of studies utilizing chronic wound-healing models [ 15 , 16 , 17 , 18 ] and other revascularization strategies [ 19 , 20 ]. Prior work from our group has shown that a reduction in HIF-1α expression in elderly and diabetic mice causes impairments in wound healing [ 21 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Chitosan Particles Complexed with CA5-HIF-1α Plasmids Increase Angiogenesis and Improve Wound Healing

Born,

Bengali,

Hsu

et al. 2023

IJMS

View full text Add to dashboard Cite

Wound therapies involving gene delivery to the skin have significant potential due to the advantage and ease of local treatment. However, choosing the appropriate vector to enable successful gene expression while also ensuring that the treatment’s immediate material components are conducive to healing itself is critical. In this study, we utilized a particulate formulation of the polymer chitosan (chitosan particles, CPs) as a non-viral vector for the delivery of a plasmid encoding human CA5-HIF-1α, a degradation resistant form of HIF-1α, to enhance wound healing. We also compared the angiogenic potential of our treatment (HIF/CPs) to that of chitosan particles containing only the plasmid backbone (bb/CPs) and the chitosan particle vector alone (CPs). Our results indicate that chitosan particles exert angiogenic effects that are enhanced with the human CA5-HIF-1α-encoded plasmid. Moreover, HIF/CPs enhanced wound healing in diabetic db/db mice (p < 0.01), and healed tissue was found to contain a significantly increased number of blood vessels compared to bb/CPs (p < 0.01), CPs (p < 0.05) and no-treatment groups (p < 0.01). Thus, this study represents a method of gene delivery to the skin that utilizes an inherently pro-wound-healing polymer as a vector for plasmid DNA that has broad application for the expression of other therapeutic genes.

show abstract

Hypoxia enhances the protective effects of placenta-derived mesenchymal stem cells against scar formation through hypoxia-inducible factor-1α

Abstract: Hypoxia enhanced the protective effect of placenta-derived mesenchymal stem cells through hypoxia-inducible factor-1α and PMSCs may have a potential application in the treatment of wound.

Cited by 6 publications

References 20 publications

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Mesenchymal Stromal Cell-Conditioned Medium for Skin Diseases: A Systematic Review

Chitosan Particles Complexed with CA5-HIF-1α Plasmids Increase Angiogenesis and Improve Wound Healing

Contact Info

Product

Resources

About